{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epileptic+Syndromes",
    "query": {
      "condition": "Epileptic Syndromes"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 231,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epileptic+Syndromes&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T23:05:27.207Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06399952",
      "title": "Baker Gordon Syndrome Natural History Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rare Diseases",
        "Autism or Autistic Traits",
        "Development Delay",
        "SYT-SSX Fusion Protein Expression",
        "Sleep Disorder",
        "Epilepsy, Generalized",
        "Motor Delay"
      ],
      "interventions": [
        {
          "name": "Brain Magnetic Resonance Imaging (MRI)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Whole Genome Sequencing",
          "type": "GENETIC"
        },
        {
          "name": "Induced Pluripotential Stem Cells",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "0 Years to 99 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-04-30",
      "completion_date": "2027-05-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06399952"
    },
    {
      "nct_id": "NCT03840928",
      "title": "PatientSpot Formerly Known as ArthritisPower",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis",
        "Ankylosing Spondylitis",
        "Fibromyalgia",
        "Gout",
        "Crohn Disease",
        "Juvenile Idiopathic Arthritis",
        "Lupus Erythematosus",
        "Myositis",
        "Osteoarthritis",
        "Osteoporosis",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Scleroderma",
        "Dermatomyositis",
        "Inflammatory Bowel Diseases",
        "Polymyositis",
        "Axial Spondyloarthritis",
        "Diffuse Idiopathic Skeletal Hyperostosis",
        "Polymyalgia Rheumatica",
        "Giant Cell Arteritis",
        "Temporal Arteritis",
        "Wegener",
        "Relapsing Polychondritis",
        "Undifferentiated Connective Tissue Disease",
        "Spinal Cord Injuries",
        "Alzheimer Disease",
        "Amyotrophic Lateral Sclerosis",
        "Ataxia",
        "Bell Palsy",
        "Brain Tumor",
        "Cerebral Aneurysm",
        "Epilepsy",
        "Guillain-Barre Syndrome",
        "Headache",
        "Head Injury",
        "Hydrocephalus",
        "Lumbar Disc Disease",
        "Meningitis",
        "Multiple Sclerosis",
        "Muscular Dystrophy",
        "Neurocutaneous Syndromes",
        "Parkinson Disease",
        "Stroke",
        "Cluster Headache",
        "Tension-Type Headache",
        "Chronic Obstructive Pulmonary Disease",
        "Asthma",
        "Lung Cancer",
        "Cystic Fibrosis",
        "Sleep Apnea",
        "Eczema",
        "Alopecia",
        "Chronic Inflammation",
        "Unstable Angina",
        "Heart Attack",
        "Heart Failure",
        "Arrythmia",
        "Valve Heart Disease",
        "High Blood Pressure",
        "Congenital Heart Disease",
        "Peripheral Arterial Disease",
        "Diabetes",
        "Chronic Liver Disease",
        "Obesity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Global Healthy Living Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 40000,
      "start_date": "2015-04-01",
      "completion_date": "2025-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 1,
      "location_summary": "Upper Nyack, New York",
      "locations": [
        {
          "city": "Upper Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03840928"
    },
    {
      "nct_id": "NCT01773252",
      "title": "Right to Left Cardiac Shunt Detection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Right to Left Shunt",
        "Patent Foramen Ovale",
        "Atrial Septal Defect"
      ],
      "interventions": [
        {
          "name": "Flow Detection System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cardiox Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2012-11",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2015-11-13",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773252"
    },
    {
      "nct_id": "NCT01496612",
      "title": "Buspirone Therapy for Localized Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anxiety Disorder",
        "Seizures",
        "Epilepsy",
        "Partial Epilepsy",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Buspirone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2011-11-22",
      "completion_date": "2016-04-19",
      "has_results": true,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496612"
    },
    {
      "nct_id": "NCT05751525",
      "title": "Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurodevelopmental Disorders",
        "Intellectual Disability",
        "Development Delay",
        "ADHD",
        "Autism Spectrum Disorder",
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Royal Devon and Exeter NHS Foundation Trust",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "2 Years to 50 Years"
      },
      "enrollment_count": 21,
      "start_date": "2016-07-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05751525"
    },
    {
      "nct_id": "NCT06585605",
      "title": "A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epilepsy in Children",
        "Dyskinesias",
        "Movement Disorders in Children",
        "Neurologic Disorder",
        "Chorea",
        "Myoclonus",
        "Ataxia",
        "Epilepsy",
        "Dystonia Disorder",
        "Movement Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 500,
      "start_date": "2024-07-01",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06585605"
    },
    {
      "nct_id": "NCT02187809",
      "title": "Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "Clobazam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "1 Year to 16 Years"
      },
      "enrollment_count": 3,
      "start_date": "2015-03",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Orange, California • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02187809"
    },
    {
      "nct_id": "NCT04873869",
      "title": "Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
      ],
      "interventions": [
        {
          "name": "NBI-921352",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-31",
      "completion_date": "2023-03-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04873869"
    },
    {
      "nct_id": "NCT04615442",
      "title": "ECV - Epihunter Clinical Validation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Absence Seizures",
        "Absence Epilepsy"
      ],
      "interventions": [
        {
          "name": "Epihunter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Epihunter NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2020-05-01",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04615442"
    },
    {
      "nct_id": "NCT05064878",
      "title": "A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "CDKL5 Deficiency Disorder",
        "Generalized Tonic Clonic Seizure",
        "Epileptic Spasm",
        "Refractory Seizures"
      ],
      "interventions": [
        {
          "name": "Fenfluramine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "1 Year to 35 Years"
      },
      "enrollment_count": 87,
      "start_date": "2022-03-08",
      "completion_date": "2027-11-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-07-23T23:05:27.207Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064878"
    }
  ]
}